Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health & Life Sciences, Oliver Wyman
Senior Knowledge Expert, Health & Life Sciences, Oliver Wyman

An examination of how the astronomically deadly and expensive opioid epidemic has generated significant litigation risk for healthcare businesses.

Coverage and Claims Leader, Marsh Casualty

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.

Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences Practice, Oliver Wyman

Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe